Gelonghui, April 29 | Cornerstone Pharmaceutical-B (02616.HK) announced that the company was informed by Yang Jianxin, CEO, R&D President and Executive Director, that it purchased a total of 3.345 million shares on the open market with its own capital about six months before the announcement date. Since Yang Jianxin became CEO in August 2022, he has purchased a total of 7,529,500 shares. The purchase price range is HKD0.82 to HKD4.60. After the share purchase, Yang Jianxin held a total of about 4.97% of the company's total issued share capital at the date of the announcement.

Yang Jianxin told the company that he is full of confidence in the company's future prospects, and that the increase in the company's shares represents his belief in the company's ability to maintain steady operation while achieving rapid growth in a complex and changing market environment, as well as unremitting support for the company's growth and development. Yang Jianxin does not rule out that it may further increase its shares in the company in due course.

The company's board of directors believes that the increase in the company's shares by its CEO, R&D president and executive director reflects Yang Jianxin's long-term commitment to the company and his confidence in the company's future business prospects.